Minerva Neurosciences, Inc. Net Income (Loss) Attributable to Parent, Diluted
Minerva Neurosciences, Inc. (NERV) reported Net Income (Loss) Attributable to Parent, Diluted of -$10.91 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2026-08-07
- Minerva Neurosciences, Inc. net income (loss) attributable to parent, diluted for the quarter ending 2026-06-30 was -$10.91M.
- Minerva Neurosciences, Inc. net income (loss) attributable to parent, diluted for the quarter ending 2025-06-30 was -$3.26M.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 6 month |
|---|---|---|
| 2026-06-30 | -$10.91M 10-Q · filed 2026-08-07 | -$107.94M 10-Q · filed 2026-08-07 |
| 2025-06-30 | -$3.26M 10-Q · filed 2026-08-07 | -$7.01M 10-Q · filed 2026-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |